Gene: HLA-DRB5

3127
-
major histocompatibility complex, class II, DR beta 5
protein-coding
6p21.32
Ensembl:ENSG00000198502 MIM:604776 Vega:OTTHUMG00000031027 UniprotKB:Q30154
NC_000006.12
PubMed
0   ANCO-SNPs
ND
1   
3.551e-2 (AD)  5.741e-1 (ND)   (Frontal_Cortex)
NA (AD)  NA (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
HLA-DRB10.824
HLA-DPA10.743
HLA-DRA0.724
CD740.717
C1QA0.701
PARVG0.699
HCLS10.698
CD370.693
C1QC0.691
MYO1F0.689

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ANKRD55-0.368
CRH-0.364
CYP1A1-0.357
ST6GAL2-0.352
HES5-0.345
ATP2C2-0.344
WNT7A-0.327
CPLX3-0.327
ABCD2-0.324
MARCH4-0.323

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
D001151ArsenicArsenic affects the methylation of HLA-DRB5 gene27838757
D019256Cadmium ChlorideCadmium Chloride results in increased expression of HLA-DRB5 mRNA18804290
D020111Chlorodiphenyl (54% Chlorine)Chlorodiphenyl (54% Chlorine) results in increased expression of HLA-DRB5 mRNA18804290
D003561CytarabineCytarabine results in decreased expression of HLA-DRB5 mRNA21198554
D002945Cisplatin[Cisplatin co-treated with panobinostat] affects the expression of HLA-DRB5 mRNA21791302
D001556LindaneLindane results in increased expression of HLA-DRB5 mRNA18804290
C473384lumiracoxibHLA-DRB5 gene SNP affects the susceptibility to lumiracoxib20639878
D008748MethylcholanthreneMethylcholanthrene results in increased expression of HLA-DRB5 mRNA18804290
D008942MitoxantroneHLA-DRB5 protein affects the susceptibility to Mitoxantrone16217747
C523799MRK 003MRK 003 results in decreased expression of HLA-DRB5 mRNA21169257
D010165PalladiumHLA-DRB5 gene polymorphism affects the susceptibility to Palladium8725357
C496932panobinostat[Cisplatin co-treated with panobinostat] affects the expression of HLA-DRB5 mRNA21791302
C023036perfluorooctanoic acidperfluorooctanoic acid results in increased expression of HLA-DRB5 mRNA18804290
D011078Polychlorinated BiphenylsPolychlorinated Biphenyls affects the expression of HLA-DRB5 mRNA21334430
C005556propionaldehydepropionaldehyde results in decreased expression of HLA-DRB5 mRNA26079696
C016766sulforafansulforafan results in decreased expression of HLA-DRB5 mRNA26833863
C061133tamibarotenetamibarotene results in increased expression of HLA-DRB5 mRNA17229644
D014635Valproic AcidValproic Acid results in decreased methylation of HLA-DRB5 gene29154799
C088658zoledronic acidzoledronic acid results in increased expression of HLA-DRB5 mRNA24714768

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0042605peptide antigen binding-ISS20356827  
GO ID GO Term Qualifier Evidence PubMed
GO:0019886antigen processing and presentation of exogenous peptide antigen via MHC class II-TAS-  
GO:0050852T cell receptor signaling pathway-TAS-  
GO:0060333interferon-gamma-mediated signaling pathway-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000139Golgi membrane-TAS-  
GO:0005765lysosomal membrane-IDA18305173  
GO:0005765lysosomal membrane-TAS-  
GO:0005886plasma membrane-TAS-  
GO:0012507ER to Golgi transport vesicle membrane-TAS-  
GO:0030658transport vesicle membrane-TAS-  
GO:0030666endocytic vesicle membrane-TAS-  
GO:0030669clathrin-coated endocytic vesicle membrane-TAS-  
GO:0031902late endosome membrane-IDA18305173  
GO:0032588trans-Golgi network membrane-TAS-  
GO:0042613MHC class II protein complex-ISS20356827  
GO:0070062extracellular exosome-HDA12519789  20458337  
GO:0071556integral component of lumenal side of endoplasmic reticulum membrane-TAS-  
KEGG ID KEGG Term
hsa04145Phagosome
hsa04514Cell adhesion molecules (CAMs)
hsa04612Antigen processing and presentation
hsa04640Hematopoietic cell lineage
hsa04672Intestinal immune network for IgA production
hsa04940Type I diabetes mellitus
hsa05140Leishmaniasis
hsa05145Toxoplasmosis
hsa05150Staphylococcus aureus infection
hsa05310Asthma
hsa05320Autoimmune thyroid disease
hsa05322Systemic lupus erythematosus
hsa05323Rheumatoid arthritis
hsa05330Allograft rejection
hsa05332Graft-versus-host disease
hsa05416Viral myocarditis
Reactome ID Reactome Term Evidence
R-HSA-1280215Cytokine Signaling in Immune systemTAS
R-HSA-1280218Adaptive Immune SystemTAS
R-HSA-168256Immune SystemTAS
R-HSA-202403TCR signalingTAS
R-HSA-202424Downstream TCR signalingTAS
R-HSA-202427Phosphorylation of CD3 and TCR zeta chainsTAS
R-HSA-202430Translocation of ZAP-70 to Immunological synapseTAS
R-HSA-202433Generation of second messenger moleculesTAS
R-HSA-2132295MHC class II antigen presentationTAS
R-HSA-388841Costimulation by the CD28 familyTAS
R-HSA-389948PD-1 signalingTAS
R-HSA-877300Interferon gamma signalingTAS
R-HSA-913531Interferon SignalingTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
26272072An Immunochip-based interaction study of contrasting interaction effects with smoking in ACPA-positive versus ACPA-negative rheumatoid arthritis. (2016 Jan)Jiang XRheumatology (Oxford)